Clinical trial
GW679769 In Fibromyalgia
NCT00264628 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00264628 |
|---|---|
| Title | GW679769 In Fibromyalgia |
| Official title | An Outpatient, Randomised, Double-blind, Placebo Controlled, Parallel Group Exploratory Study to Evaluate Safety, Tolerability and Efficacy of GW679769 in Patients With Fibromyalgia Syndrome Comorbid With Depression. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Depressive Disorder, Depression, Fibromyalgia |
| Intervention type | Drug |
| Interventions | GW679769 |
| Enrollment | 8 |
| Start date | Oct 1, 2005 |
| Primary completion | Sep 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Dec 13, 2005 |
| Last update posted | Apr 16, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: